Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Wittebole

Showing results (81-90 of 111) with videos related to

Pageof 12
Sort By:
Shock (Augusta, Ga.)|July 13, 2013
S100A12 and soluble receptor for advanced glycation end products levels during human severe sepsisAhmed Achouiti, Dirk Föll, Thomas Vogl, et al.
Annals of Intensive Care|July 23, 2016
Aerosol delivery with two ventilation modes during mechanical ventilation: a randomized studyJonathan Dugernier, Gregory Reychler, Xavier Wittebole, et al.
Critical Care Medicine|December 17, 2013
Evaluating the efficacy and safety of two doses of the polyclonal anti-tumor necrosis factor-α fragment antibody AZD9773 in adult patients with severe sepsis and/or septic shock: randomized, double-blind, placebo-controlled phase IIb study*Gordon R Bernard, Bruno Francois, Jean-Paul Mira, et al.
Critical Care (London, England)|February 26, 2021
Temporal changes in the epidemiology, management, and outcome from acute respiratory distress syndrome in European intensive care units: a comparison of two large cohortsYasser Sakr, Bruno François, Jordi Solé-Violan, et al.
Critical Care Medicine|September 29, 2007
Systemic and local high mobility group box 1 concentrations during severe infectionMarieke A D van Zoelen, Pierre-François Laterre, Suzanne Q van Veen, et al.
Journal of Critical Care|November 2, 2023
The safety and efficacy of stem cells for the treatment of severe community-acquired bacterial pneumonia: A randomized clinical trialPierre-François Laterre, Miguel Sánchez García, Tom van der Poll, et al.
Intensive Care Medicine|May 30, 2020
Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trialBruno François, Xavier Wittebole, Ricard Ferrer, et al.
American Journal of Respiratory and Critical Care Medicine|September 19, 2009
Expression and role of myeloid-related protein-14 in clinical and experimental sepsisMarieke A D van Zoelen, Thomas Vogl, Dirk Foell, et al.
Intensive Care Medicine|June 26, 2015
The Surviving Sepsis Campaign bundles and outcome: results from the International Multicentre Prevalence Study on Sepsis (the IMPreSS study)Andrew Rhodes, Gary Phillips, Richard Beale, et al.
The Journal of Antimicrobial Chemotherapy|August 26, 2022
Binding of temocillin to plasma proteins in vitro and in vivo: the importance of plasma protein levels in different populations and of co-medicationsPerrin Ngougni Pokem, Peter Matzneller, Steven Vervaeke, et al.
Pageof 12

Showing results (81-90 of 111) with videos related to

Sort By:
Pageof 12
Shock (Augusta, Ga.)|July 13, 2013
S100A12 and soluble receptor for advanced glycation end products levels during human severe sepsisAhmed Achouiti, Dirk Föll, Thomas Vogl, et al.
Annals of Intensive Care|July 23, 2016
Aerosol delivery with two ventilation modes during mechanical ventilation: a randomized studyJonathan Dugernier, Gregory Reychler, Xavier Wittebole, et al.
Critical Care Medicine|December 17, 2013
Evaluating the efficacy and safety of two doses of the polyclonal anti-tumor necrosis factor-α fragment antibody AZD9773 in adult patients with severe sepsis and/or septic shock: randomized, double-blind, placebo-controlled phase IIb study*Gordon R Bernard, Bruno Francois, Jean-Paul Mira, et al.
Critical Care (London, England)|February 26, 2021
Temporal changes in the epidemiology, management, and outcome from acute respiratory distress syndrome in European intensive care units: a comparison of two large cohortsYasser Sakr, Bruno François, Jordi Solé-Violan, et al.
Critical Care Medicine|September 29, 2007
Systemic and local high mobility group box 1 concentrations during severe infectionMarieke A D van Zoelen, Pierre-François Laterre, Suzanne Q van Veen, et al.
Journal of Critical Care|November 2, 2023
The safety and efficacy of stem cells for the treatment of severe community-acquired bacterial pneumonia: A randomized clinical trialPierre-François Laterre, Miguel Sánchez García, Tom van der Poll, et al.
Intensive Care Medicine|May 30, 2020
Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trialBruno François, Xavier Wittebole, Ricard Ferrer, et al.
American Journal of Respiratory and Critical Care Medicine|September 19, 2009
Expression and role of myeloid-related protein-14 in clinical and experimental sepsisMarieke A D van Zoelen, Thomas Vogl, Dirk Foell, et al.
Intensive Care Medicine|June 26, 2015
The Surviving Sepsis Campaign bundles and outcome: results from the International Multicentre Prevalence Study on Sepsis (the IMPreSS study)Andrew Rhodes, Gary Phillips, Richard Beale, et al.
The Journal of Antimicrobial Chemotherapy|August 26, 2022
Binding of temocillin to plasma proteins in vitro and in vivo: the importance of plasma protein levels in different populations and of co-medicationsPerrin Ngougni Pokem, Peter Matzneller, Steven Vervaeke, et al.
Pageof 12